Fri, Aug 29, 2014, 5:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Summer, I think the results for IPI-504 may be the worst clinical trial results I've ever seen, certainly for a drug that got as far as phase 2. Virtually no improvement in PSA or tumor burden, the chosen endpoints, and "unacceptable levels of toxicity" including a couple of deaths (in a small population) that appeared to be drug-related.

      Fortunately, OGX-427 is targeting a different heat shock protein in a different way, and if the phase 1 results mean anything the phase 2 results will at least be better than those for Infinity's drug.

      I share the hope you expressed in a different post that OGXI will finally provide some timeline guidance on its trials tomorrow. OGXI has had quite a news drought of late. I don't think we've heard from Cormack since the Q1 conference call. I can barely remember what he sounds like.

      A minor observation: I notice that they no longer seem to be listing SN-2310 as a product candidate. I guess they've given up on trying to outlicense it.

 
OGXI
3.31+0.01(+0.30%)Aug 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.